ALISO VIEJO, CALIF., July 30 /CNW/ - Valeant Pharmaceuticals
International (NYSE:VRX) today announced that it has launched the Xyrem
Success Program(TM) for (C)Xyrem(R) (sodium oxybate), the first and only
product approved in Canada to treat cataplexy, a sudden loss of muscle tone
associated with narcolepsy. Valeant will distribute Xyrem in Canada through
its specialty sales force and will be promoted exclusively to neurologists,
psychiatrists, pulmonologists, and sleep specialists who treat patients with
narcolepsy.
